UAE-based Mubadala Investment Company has invested in US-based PCI Pharma, a pharmaceutical and biopharmaceutical global supply chain solutions provider, the media reported.
The terms of the transactions were not disclosed.
With regard to the investment in PCI Pharma, head of Pharma & Medtech at Mubadala, Camilla Macapili Languille told the media, “Outsourced pharmaceutical services has been a key investment theme for us over the past few years, and we are excited to be partnering with one of the global leaders in this industry.
“We have been particularly impressed by the quality and depth of PCI’s management team, as well as the company’s strong execution track record, impeccable values, and distinct vision for the long-term development of their business. We have strong conviction in the company’s growth trajectory and are committed to working with Kohlberg and Partners Group to ensure their long-term success.”
The Philadelphia-headquartered company spans a global footprint of 25 facilities across six countries and employs 3,900 people worldwide.
Through the investment in PCI Pharma, Mubadala expects to improve its customer service experience and enable its customers to bring lifesaving biopharmaceutical therapies to market.
Earlier this year, Mubadala Investment Company acquired a 1.85 percent stake in India’s Reliance Jio in a deal worth $1.21 billion.
Launched in 2016, Reliance Jio has established itself as a telecom giant in India in a short spell due to its competitive pricing strategy. Backed by multibillionaire Mukesh Ambani’s Reliance Jio disrupted the Indian telecom sector which led to many telcos exiting the market with Vodafone on the brink of shutting down its business in India.